TITLE

SHIRE GETS FDA APPROVABLE LETTER FOR DAYTRANA FOR ADHD

PUB. DATE
February 2006
SOURCE
Worldwide Biotech;Feb2006, Vol. 18 Issue 2, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the approval given by the U.S. Food and Drug Administration to DAYTRANA, an investigational methylphenidate transdermal system developed by Shire PLC. Use of the drug for treating attention deficit hyperactivity disorder (ADHD) in children; Remarks from company CEO Matthew Emmens regarding the drug approval; Clinical information on ADHD.
ACCESSION #
20451863

 

Related Articles

  • SHIRE GETS FDA APPROVABLE LETTER FOR DAYTRANA FOR ADHD.  // Worldwide Videotex Update;Feb2006, Vol. 25 Issue 2, p119 

    The article reports on an approvable letter received by Shire plc from the U.S. Food and Drug Administration for its DAYTRANA or methylphenidate transdermal system for children with attention deficit hyperactivity disorder. The approvable letter includes proposed labeling, requests for data...

  • Shire/Noven: MTS back on track.  // PharmaWatch: Monthly Review;Sep2005, Vol. 4 Issue 9, p18 

    Reports on the submission of an application for a drug to treat pediatric attention-deficit hyperactivity disorder to the U.S. Food and Drug Administration by Shire Pharmaceuticals Group PLC and Noven Pharmaceuticals Inc. Information on a transdermal delivery system for methylphenidate; Benefits...

  • Opinion: Shire: Intuniv approval diversifies ADHD portfolio.  // PharmaWatch: Monthly Review;Oct2009, Vol. 8 Issue 10, p14 

    The author focuses on the announcement of Shire Pharmaceuticals Group PLC on the approval by the Food & Drug Administration (FDA) of the Intuniv extended release tablets for the treatment of attention-deficit hyperactivity disorder (ADHD). It notes that Intuniv represents Shire's first venture...

  • Shire: Vyvanse grows up.  // PharmaWatch: Monthly Review;Jun2008, Vol. 7 Issue 6, p14 

    The article reports on the approval set by the U.S. Food and Drug Administration (FDA) for Vyvanse by Shire Pharmaceuticals Group PLC as treatment for adult attention-deficit hyperactivity disorder (ADHD). FDA recommended the drug as the only once-daily prodrug stimulant available to treat...

  • Noven/Shire: a patch in the balance.  // PharmaWatch: Monthly Review;Jan2006, Vol. 5 Issue 1, p21 

    The article reports that the scientists of the U.S. Food and Drug Administration (FDA) have cast doubt on the eligibility of Noven Pharmaceutical Inc. and Shire Pharmaceutical Group PLC's Daytrana for getting approved. The briefing documents posted at the web site of the FDA advise that Daytrana...

  • Trandermal ADHD drug gets FDA nod.  // Drug Topics;5/8/2006, Vol. 150 Issue 9, p6 

    The article reports on the approval given by the U.S. food and Drug Administration to Daytrana, a new form of delivery for methylphenidate, for the treatment of attention deficit hyperactivity disorder. The drug from Shire Pharmaceuticals Group PLC, is a transdermal system that will deliver a...

  • ADHD therapy to be applied transdermally. Belden, Heidi // Drug Topics;5/22/2006, Vol. 150 Issue 10, p14 

    The article reports on the redevelopment of the Daytrana drug from Shire PLC as a treatment for children diagnosed with attention deficit or hyperactivity disorder (ADHD) in the U.S. Daytrana is a non-oral drug which was approved by the Food and Drug Administration to manage hyperactivity in...

  • Shire and Noven resubmit application for ADHD patch.  // PharmaWatch: CNS;Sep2005, Vol. 4 Issue 9, p12 

    This article reports that Shire Pharmaceuticals Inc. and Noven Pharmaceuticals Inc. have resubmitted to the U.S. FDA a new drug application for MTS, a drug to treat attention deficit hyperactivity disorder in children aged six to 12. MTS is delivered through the patient's skin via a patch. ADHD...

  • ADHD drug given Schedule II classification.  // Drug Topics;5/21/2007, Vol. 151 Issue 10, 0 p10 

    The article reports that attention-deficit hyperactivity disease (ADHD) prodrug lisdexamfetamine dimesylate with a brand name Vyvanse from Shire Pharmaceuticals Group PLC will be considered a Schedule II substance, according to the U.S. Drug Enforcement Association. The consideration of the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics